Every 424B that Medicus Pharma Ltd. (MDCX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow MDCX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MDCX filings page.
Medicus Pharma Ltd.'s prospectus identifies 3,245,595 common shares issuable upon exercise of warrants. The company announced a 50-to-one consolidation of its common shares, effective October 12, 2026. Each 50 issued and outstanding common shares will be exchanged for one new common share, and the ticker symbol will remain MDCX.
No fractional shares will be issued; holders otherwise entitled to a fraction will be rounded down and paid cash in lieu. The company also stated that exercise prices and share counts for outstanding equity awards, convertible securities and warrants will be adjusted proportionately. The company said the consolidation is intended to increase the bid price and enable it to regain compliance with Nasdaq's minimum bid price requirement.
Medicus Pharma Ltd. (MDCX) filed a prospectus supplement covering 3,245,595 common shares issuable upon exercise of outstanding public warrants at $4.64 per share, expiring November 15, 2029. The supplement incorporates two recent current reports into the existing Form S-1 prospectus.
On September 4, 2026, officers and employees elected to take approximately $1.45 million of cash bonuses in equity, and the company issued an aggregate 8,529,412 restricted common shares based on a Nasdaq closing price of $0.1705 per share. Separately, on September 11, 2026, Medicus Pharma and YA II PN, LTD. mutually terminated a Standby Equity Purchase Agreement that had permitted up to $15.0 million of common share sales, with no borrowings outstanding and no termination fees due.
Medicus Pharma Ltd. (MDCX) filed a prospectus supplement registering 3,245,595 common shares issuable upon exercise of outstanding warrants and updating investors with a new collaboration disclosure. The attached Form 8-K describes a Co-Development and License Agreement under which Pfizer granted Medicus exclusive, worldwide rights to develop and commercialize CD228V, an early clinical-stage antibody-drug conjugate targeting melanotransferrin (CD228). Medicus paid Pfizer a $12.0 million upfront fee, will owe an additional $15.0 million on the first anniversary, and received a $2.0 million Development Funding Payment to support CD228V development. Pfizer remains economically involved through potential development, regulatory and sales milestones that in aggregate exceed $1.0 billion and through low double-digit royalties on annual net sales, while Medicus retains control over development, regulatory and commercialization activities.
Medicus Pharma Ltd. is registering 3,245,595 common shares issuable upon exercise of outstanding warrants, each with a $4.64 exercise price and expiring November 15, 2029. Common shares and public warrants trade on Nasdaq as MDCX and MDCXW.
For the quarter ended June 30, 2026, Medicus reported a net loss of $11.7 million, and a six‑month loss of $20.7 million, driven by $20.1 million in operating expenses, including increased R&D for SkinJect and Teverelix. Cash and cash equivalents were $15.2 million with an additional $10.0 million of restricted cash; total assets were $27.1 million and total liabilities $28.8 million, resulting in negative shareholders’ equity of $(1.7) million.
Financing inflows for the first half of 2026 included $22.0 million of secured promissory notes, $12.4 million from an at‑the‑market program, and $4.1 million via a standby equity purchase agreement. Management discloses substantial doubt about the company’s ability to continue as a going concern without additional capital and notes a Nasdaq notice for not meeting the $1.00 minimum bid price requirement.
Medicus Pharma Ltd. files a prospectus supplement amending its Form S-1 to register 3,245,595 Common Shares issuable upon exercise of outstanding warrants. The supplement incorporates a Form 8-K dated June 3, 2026 and updates offering and corporate information.
The Public Warrants have an exercise price of $4.64 and an expiration date of November 15, 2029. The prospectus notes last reported sales prices on June 3, 2026 of the common shares at $0.3576 and the Public Warrants at $0.50. The attached Form 8-K reports shareholders ratified KPMG, elected nine directors, and approved a potential share consolidation of up to 50 pre-consolidation for 1 post-consolidation share.
Medicus Pharma Ltd. registers 3,245,595 common shares issuable upon the exercise of warrants. This prospectus supplement dated May 27, 2026 amends the Form S-1 prospectus and incorporates a Form 8-K describing a note financing and Nasdaq notice.
The Form 8-K discloses a note purchase agreement with Streeterville Capital providing a Secured Promissory Note A-1 with an original principal of $12,864,225 (including an OID of $834,225) and a Secured Promissory B Note of $10,000,000. The Company states proceeds will support clinical programs, business development and general corporate purposes, and used approximately $2.5 million to repay a prior debenture. The Company also received a Nasdaq notice for noncompliance with the $35,000,000 MVLS standard and has a 180-calendar-day period to regain compliance, until November 16, 2026.
Medicus Pharma Ltd. registers 3,245,595 common shares issuable upon exercise of warrants. This prospectus supplement (dated May 14, 2026) amends the existing prospectus and incorporates the Company's Form 10-Q for the quarter ended March 31, 2026. The supplement records the number of common shares that may be issued if outstanding warrants are exercised and updates investors with interim financials.
The attached Form 10-Q shows 56,658,164 common shares issued and outstanding as of May 7, 2026, cash of $6,365,624 at March 31, 2026, a three-month net loss of $9,042,311, and a working capital balance of $1,328,773. Management discloses substantial doubt about the Company's ability to continue as a going concern within one year.
Medicus Pharma Ltd. files a prospectus supplement to register 3,245,595 common shares issuable upon the exercise of outstanding public warrants. The supplement attaches Amendment No. 1 to the 2025 Form 10-K, which adds Part III disclosures including director and executive officer biographies, board and committee composition, executive compensation tables, and governance policies.
The prospectus notes the Public Warrants carry a $4.64 exercise price and expire November 15, 2029; last reported April 28, 2026 prices were $0.30 per common share and $0.7199 per Public Warrant. Shares outstanding were 41,818,092 as of April 15, 2026.
Medicus Pharma Ltd. filed a Prospectus Supplement No. 1 and attached a Form 8-K to register 3,245,595 common shares issuable upon the exercise of warrants. The supplement reflects an ATM Upsize: the company amended its Equity Distribution Agreement to permit up to $50,000,000 of at-the-market sales and states it has raised approximately $11.5 million under the ATM Offering Program. The filing discloses last reported sales prices of the common shares at $0.3321 and Public Warrants at $0.2901. The company also received Nasdaq notice for noncompliance with the minimum $1.00 bid-price rule and has until October 19, 2026 to regain compliance.
MDCX amends its prospectus supplement to offer common shares having an aggregate offering price of up to $50,000,000 under an amended equity distribution agreement dated April 23, 2026. The Sales Agreement names Maxim Group LLC and Yorkville Securities, LLC as Agents. The company’s common shares trade on Nasdaq under MDCX; the prospectus cites a closing share price of $0.339 and Public Warrants closing at $0.2901 as of April 22, 2026.
Medicus Pharma Ltd. registers up to 1,397,184 common shares via a prospectus supplement to its Form S-1, and this supplement incorporates the Form 10-K filed on March 25, 2026. The supplement updates the offering materials and amends the Prospectus effective November 14, 2025.
The Form 10-K included by reference summarizes Medicus’s operations, including completion of the Antev acquisition for approximately $2.97M plus 1,603,164 shares, clinical progress for D-MNA (Phase 2 topline results) and regulatory clearances and study-may-proceed letters for its Teverelix programs.
Medicus Pharma Ltd. amends its May 29, 2025 prospectus to register 2,260,000 common shares issuable upon the exercise of outstanding public warrants. The supplement attaches the company's Form 10-K and updates disclosures, including that the public warrants have an exercise price of $4.64 and expire on November 15, 2029. The filing cites last reported sales prices on March 24, 2026 of $0.49 per common share and $0.57 per Public Warrant, and states there were 39,362,109 common shares outstanding as of March 17, 2026. The Form 10-K (fiscal year ended December 31, 2025) also summarizes clinical-stage programs (SkinJect D-MNA and Antev/Teverelix), the August 29, 2025 acquisition of Antev, contingent milestone consideration arrangements, and recent regulatory interactions and topline Phase 2 D-MNA results.
Medicus Pharma Ltd. registers 1,115,500 common shares issuable upon the exercise of warrants under a prospectus supplement amending the April 10, 2025 prospectus.
The supplement attaches the Form 10-K for the fiscal year ended December 31, 2025 and updates related disclosures. The Public Warrants have an exercise price of $4.64 and an expiration date of November 15, 2029. The common shares and Public Warrants trade on Nasdaq under the symbols MDCX and MDCXW. Shares outstanding were 39,362,109 common shares as of March 17, 2026.
Medicus Pharma Ltd. registers up to 7,500,000 common shares via a prospectus supplement to its effective Registration Statement on Form S-1.
The supplement incorporates the Company’s Form 10-K filed March 25, 2026, and notes 39,362,109 common shares outstanding as of March 17, 2026. The Company’s common shares trade on Nasdaq under the symbol MDCX; the last reported sales price on March 24, 2026 was $0.49.
Medicus Pharma Ltd. registers 1,115,500 common shares issuable upon the exercise of warrants, as set forth in Prospectus Supplement No. 22 dated March 6, 2026. The supplement attaches a Current Report on Form 8-K and updates the April 10, 2025 prospectus.
The supplement restates the Public Warrants' exercise price $4.64 and expiration date November 15, 2029, and notes last reported Nasdaq prices on March 5, 2026 of $0.68 (common share) and $1.00 (Public Warrant). The Form 8-K discloses prior unregistered sales under a SEPA to YA II PN, Ltd. totaling 4,471,038 common shares for aggregate consideration of $3,846,910, and that part of those proceeds prepaid a Yorkville debenture.
Medicus Pharma Ltd. files a prospectus supplement registering up to 1,397,184 common shares and amends the Prospectus dated November 14, 2025 to incorporate its Form 8-K dated March 6, 2026. The supplement notes the company completed multiple unregistered sales to Yorkville under a Standby Equity Purchase Agreement, totaling $3,846,910 for 4,471,038 common shares as detailed in the attached table.
Medicus Pharma Ltd. registers 2,260,000 common shares issuable upon the exercise of public warrants under a prospectus supplement dated March 6, 2026. This supplement amends the May 29, 2025 prospectus and incorporates a Form 8-K filed March 6, 2026.
The Form 8-K discloses prior sales under a Standby Equity Purchase Agreement totaling 4,471,038 common shares for aggregate consideration of $3,846,910 (sales dated December 19, 2025 through March 6, 2026). The supplement notes the public warrants have an exercise price of $4.64 and expire on November 15, 2029; market prices quoted were $0.68 per common share and $1.00 per Public Warrant as of March 5, 2026.
Medicus Pharma Ltd. files a prospectus supplement registering up to 7,500,000 common shares and attaches a Form 8-K reporting equity financings under a Standby Equity Purchase Agreement.
The Form 8-K lists completed SEPA sales totaling 4,471,038 common shares for aggregate consideration of $3,846,910, and states Yorkville may purchase additional shares "subject to the satisfaction or waiver of the conditions and limitations set forth in the SEPA". The company notes its Nasdaq last sale price was $0.68.
Medicus Pharma Ltd. filed a prospectus supplement covering the resale of up to 2,680,000 common shares tied to previously issued warrants. The supplement adds information from a new current report about a warrant inducement agreement and recent equity sales.
On December 5, 2025 the company agreed with an accredited institutional holder to amend existing warrants for up to 2,680,000 common shares to an exercise price of $1.92 per share. In return, the holder will receive new unregistered warrants for up to 4,020,000 additional common shares at $2.00 per share, expiring on June 5, 2031, with one series allowing the company to force exercise if the 10‑day average VWAP reaches $10.00. Gross proceeds from the exercise of the existing warrants are expected to be approximately $5.1 million, before expenses and a 6.0% cash fee to Maxim Group LLC.
The company plans to register the resale of the shares underlying the new warrants by filing a new registration statement within 60 days and keeping it effective until the original holder can sell under Rule 144 without limits. Separately, under its Standby Equity Purchase Agreement with Yorkville, Medicus Pharma sold 680,893 common shares for aggregate consideration of $1,500,905 and used part of the net proceeds to prepay a portion of an outstanding debenture. Its common shares trade on the Nasdaq Capital Market under the symbol MDCX, with a last reported price of $2.05 on December 5, 2025.
Medicus Pharma Ltd. has filed a prospectus supplement relating to 1,115,500 common shares issuable upon the exercise of previously registered warrants and uses it to update investors on new financing activity. The company entered into a warrant inducement agreement with an institutional holder to amend existing warrants to buy up to 2,680,000 common shares at $1.92 per share, in exchange for the holder receiving 4,020,000 new unregistered warrants with a $2.00 exercise price, expiring June 5, 2031. One series of these new warrants allows the company, under certain conditions, to force exercise if the average share VWAP reaches $10.00 over ten trading days, and the company expects approximately $5.1 million in gross proceeds from the existing warrant exercises before a 6% fee to its advisor.
The filing also details recent sales of 680,893 common shares to Yorkville under a standby equity purchase agreement, generating about $1,500,905 in aggregate consideration, with part of the net proceeds used to prepay a portion of a debenture owed to Yorkville. Medicus plans to register the resale of the shares underlying the new warrants in a future registration statement and notes that the new warrants and related shares are currently unregistered, issued under a private offering exemption.
Medicus Pharma Ltd. updates its prospectus for an offering of up to 2,680,000 common shares and attaches a recent current report. The supplement incorporates a Form 8-K that details executive leadership changes while keeping the original S-1 prospectus in effect.
The company’s common shares trade on Nasdaq under the symbol MDCX, with a last reported price of $1.73 on December 3, 2025. The filing confirms Medicus Pharma’s status as an emerging growth company and reminds investors of the high risks described in the underlying prospectus.
The Form 8-K reports that Chief Financial Officer James Quinlan resigned as an officer and employee effective November 28, 2025, after being on medical leave since September 12, 2025. Effective December 1, 2025, President Carolyn Bonner, who had been acting CFO, was appointed Chief Financial Officer and will continue serving as President under a five-year employment agreement with a $395,000 base salary and escalating target bonus opportunities.
Medicus Pharma Ltd. has filed a prospectus supplement covering up to 3,710,000 common shares under an existing S-1 registration and attached its latest quarterly report. For the nine months ended September 30, 2025, the company reported a net loss of $27,259,804, driven by operating expenses of $26,568,702, including an $8,717,475 in-process R&D charge for the Antev Teverelix acquisition. Cash and cash equivalents were $8,662,091, with total assets of $9,977,661 and a shareholders’ deficit of $804,890. A going concern warning highlights reliance on continued financings, including an $8,000,000 debenture and a $15,000,000 standby equity purchase agreement, while common shares outstanding reached 22,029,144 as of November 11, 2025.
Medicus Pharma Ltd. has filed a prospectus supplement registering up to 1,397,184 common shares and incorporating its latest quarterly report. The company is a clinical-stage biotech developing dissolvable microneedle patches for skin cancers and, through newly acquired Antev, a GnRH antagonist (Teverelix) for prostate-related indications.
As of September 30, 2025, Medicus held $8.7 million in cash and total assets of about $10.0 million, but current liabilities of $10.7 million left shareholders with a deficit of roughly $0.8 million. There were 22,029,144 common shares outstanding as of November 11, 2025, and the Nasdaq share price was $2.26 on November 13, 2025.
The company reported a net loss of $15.98 million for the quarter and $27.26 million for the nine months ended September 30, 2025, driven by higher general and administrative and R&D spending and an $8.72 million in-process R&D charge related to Teverelix. Operations have been funded by equity offerings, warrant exercises, a standby equity purchase agreement and new debentures, and management discloses substantial doubt about the ability to continue as a going concern without additional capital.
Medicus Pharma Ltd. is registering 2,260,000 common shares issuable upon the exercise of warrants under its Form S-1, via a new prospectus supplement that incorporates its Quarterly Report on Form 10-Q for the period ended September 30, 2025. The company reported a net loss attributable to common shareholders of $20,935,830 for the quarter and $32,214,322 for the nine months, driven by higher general and administrative costs, increased research and development spending, and an $8,717,475 charge for in-process R&D from the Antev acquisition. Cash and cash equivalents were $8,662,091 with debentures of $6,785,812 and a shareholders’ deficit of $804,890. The company discloses substantial doubt about its ability to continue as a going concern and highlights reliance on warrant exercises, a standby equity purchase agreement and other financings. As of November 11, 2025, it had 22,029,144 common shares outstanding.
Medicus Pharma Ltd. is registering 1,115,500 common shares issuable upon exercise of existing public warrants. The warrants have a $4.64 exercise price and expire on November 15, 2029, while the common shares and warrants trade on Nasdaq under "MDCX" and "MDCXW." As of November 11, 2025, the company had 22,029,144 common shares outstanding.
For the nine months ended September 30, 2025, Medicus reported a net loss of $27.3 million, driven by $26.6 million in operating expenses, including $12.7 million in general and administrative costs, $5.1 million in R&D, and an $8.7 million in-process R&D charge from the Antev acquisition. Shareholders’ equity shifted to a deficit of about $0.8 million despite multiple equity raises and warrant exercises.
Cash and cash equivalents were $8.7 million against a working capital deficit and debentures of $6.8 million. Management discloses substantial doubt about the company’s ability to continue as a going concern and highlights reliance on additional financings, including a standby equity purchase agreement of up to $15 million, warrant exercises, and other capital sources to fund ongoing clinical programs.
Medicus Pharma Ltd. has filed a prospectus supplement covering up to 7,500,000 common shares under its Form S-1, updating the offering with new quarterly information. The attached Form 10-Q shows a clinical-stage biotech expanding its pipeline but generating substantial losses as it funds development and acquisitions.
For the nine months ended September 30, 2025, the company recorded a net loss of $27,259,804, driven by $26,568,702 in operating expenses that include $8,717,475 of in-process R&D expense from the Antev acquisition, higher general and administrative costs, and increased research and development spending. Cash and cash equivalents were $8,662,091 as of September 30, 2025.
Medicus raised capital through a Regulation A unit offering, a June 2025 public offering, warrant exercises, a standby equity purchase agreement and new debentures, but still reported a shareholders’ deficit and a working capital deficit. The company discloses substantial doubt about its ability to continue as a going concern without additional financing. As of November 11, 2025, it had 22,029,144 common shares issued and outstanding.
Medicus Pharma filed a prospectus supplement to its Form S-1 covering up to 3,710,000 common shares. The supplement attaches a Current Report on Form 8-K.
The 8-K details recent sales of 1,088,048 common shares to Yorkville under the Standby Equity Purchase Agreement, for approximate aggregate consideration of $2,526,364, across multiple issuances from September 8 to October 16, 2025. The company states it has used part of the net proceeds to prepay a portion of a debenture outstanding with Yorkville.
Medicus Pharma’s common shares trade on Nasdaq as MDCX; the last reported sales price was $2.41 on October 16, 2025. The company is an emerging growth company under SEC rules.
Medicus Pharma filed a prospectus supplement covering 2,260,000 common shares issuable upon the exercise of warrants. The company’s common shares and the public warrants (exercise price $4.64, expiring November 15, 2029) trade on Nasdaq as MDCX and MDCXW. On October 16, 2025, the last reported prices were $2.41 for the shares and $0.90 for the warrants.
Attached, a Current Report details recent sales under a Standby Equity Purchase Agreement with Yorkville. Between September 8 and October 16, 2025, the company sold 1,088,048 common shares to Yorkville for aggregate consideration of $2,526,364, in transactions exempt from registration under Section 4(a)(2). The company used part of the net proceeds to prepay a portion of a debenture outstanding with Yorkville.
Medicus Pharma Ltd. filed a prospectus supplement updating its S-1 to cover 1,115,500 common shares issuable upon the exercise of warrants. The supplement incorporates a new Form 8-K.
The company also reported under the SEPA with Yorkville that it sold 1,088,048 common shares across multiple dates for approximately $2,526,364 in aggregate consideration, and used part of the net proceeds to prepay a portion of a debenture with Yorkville. The common shares and public warrants trade on Nasdaq as MDCX and MDCXW; on October 16, 2025, last reported prices were $2.41 and $0.90, respectively. The public warrants have a $4.64 exercise price and expire on November 15, 2029.